{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:54Z","timestamp":1794475794087,"version":"4.9.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1215-16"],"award-info":[{"award-number":["1215-16"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015035","name":"National Foundation of Elites","doi-asserted-by":"publisher","award":["721005"],"award-info":[{"award-number":["721005"]}],"id":[{"id":"10.13039\/501100015035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128683","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:07:54Z","timestamp":1778296074000},"page":"128683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi"],"prefix":"10.1016","volume":"84","author":[{"given":"Zeinab","family":"Pourhashem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Siasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Nourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemen","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar J.","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hediyeh","family":"vand-Rajabpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbasali","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakineh","family":"Pirahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Zargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid Dinparast","family":"Djadid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedigheh","family":"Zakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram Abouie","family":"Mehrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128683_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101073","article-title":"WHO world malaria report 2024","volume":"6","author":"Venkatesan","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128683_bb0010","doi-asserted-by":"crossref","first-page":"6619010","DOI":"10.1155\/2024\/6619010","article-title":"The malaria burden: a South African perspective","volume":"2024","author":"Balmith","year":"2024","journal-title":"J Trop Med"},{"key":"10.1016\/j.vaccine.2026.128683_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00016-8","article-title":"The 2023 WHO World malaria report","volume":"5","author":"Venkatesan","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128683_bb0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12879-024-09213-3","article-title":"Possible potential spread of Anopheles stephensi, the Asian malaria vector","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128683_bb0025","series-title":"Climate change, other pressures erode malaria progress","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128683_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: recent advances and new horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128683_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012309","article-title":"A new landscape for malaria vaccine development","volume":"20","author":"Laurenson","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128683_bb0040","doi-asserted-by":"crossref","unstructured":"El-Moamly AA, El-Sweify MA. Malaria vaccines: the 60-year journey of hope and final success\u2014lessons learned and future prospects. Trop Med Health 2023;51:29. doi: https:\/\/doi.org\/10.1186\/s41182-023-00516-w.","DOI":"10.1186\/s41182-023-00516-w"},{"key":"10.1016\/j.vaccine.2026.128683_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543776.2023.2190884","article-title":"Malaria vaccines","volume":"33","author":"Quagliata","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.vaccine.2026.128683_bb0050","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14760584.2024.2369583","article-title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development","volume":"23","author":"Bansal","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/IAI.00498-16","article-title":"The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines","volume":"85","author":"Espinosa","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128683_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00911-18","article-title":"Combining monophosphoryl lipid a (MPL), CpG oligodeoxynucleotide (ODN), and QS-21 adjuvants induces strong and persistent functional antibodies and T cell responses against cell-traversal protein for ookinetes and sporozoites (CelTOS) of Plasmodium falcip","volume":"87","author":"Pirahmadi","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128683_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-019-2773-3","article-title":"Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi","volume":"18","author":"Pirahmadi","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150599","article-title":"Cd loop fusion enhances the immunogenicity and the potential transmission blocking activity of Plasmodium falciparum generative cell specific 1 (GCS1) antigen","volume":"733","author":"Nourani","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2026.128683_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12936-023-04798-7","article-title":"Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine","volume":"22","author":"Pourhashem","year":"2023","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306664","article-title":"Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants","volume":"19","author":"Pourhashem","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128683_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-021-00309-4","article-title":"Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen","volume":"6","author":"Bender","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0972-9062.318308","article-title":"An analytical review of vector-and pathogen-based transmission-blocking vaccine for malaria control","volume":"59","author":"Jakhar","year":"2022","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.vaccine.2026.128683_bb0095","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nsmb.3048","article-title":"The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope","volume":"22","author":"Atkinson","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2958.2005.05024.x","article-title":"CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts","volume":"59","author":"Kariu","year":"2006","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-022-04583-w","article-title":"Malaria parasites utilize two essential plasma membrane fusogens for gamete fertilization","volume":"79","author":"Kumar","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2026.128683_bb0110","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.celrep.2017.11.024","article-title":"Targeting the conserved fusion loop of HAP2 inhibits the transmission of Plasmodium berghei and falciparum article targeting the conserved fusion loop of HAP2 inhibits the transmission of Plasmodium berghei and falciparum","volume":"21","author":"Angrisano","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.128683_bb0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.meegid.2014.01.016","article-title":"Limited genetic diversity and purifying selection in Iranian Plasmodium falciparum Generative Cell Specific 1 (PfGCS1), a potential target for transmission-blocking vaccine","volume":"22","author":"Mehrizi","year":"2014","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0120","unstructured":"Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A, et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen 2007."},{"key":"10.1016\/j.vaccine.2026.128683_bb0125","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/IAI.01222-13","article-title":"Antibodies to a single, conserved epitope in anopheles APN1 inhibit universal transmission of plasmodium falciparum and plasmodium vivax malaria","volume":"82","author":"Armistead","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128683_bb0130","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1016\/j.vaccine.2009.06.069","article-title":"Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro","volume":"27","author":"Blagborough","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128683_bb0135","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/IAI.01056-13","article-title":"Functional comparison of plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay","volume":"81","author":"Miura","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128683_bb0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14760584.2.2.219","article-title":"Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi. 529","volume":"2","author":"Evans","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14760584.2.2.305","article-title":"CpG DNA as a vaccine adjuvant","volume":"2","author":"Klinman","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.actatropica.2018.12.014","article-title":"Heterogeneity in the acquisition of naturally acquired antibodies to cell-traversal protein for ookinetes and sporozoites (CelTOS) and thrombospondin-related adhesion protein (TRAP) of Plasmodium falciparum in naturally infected patients from unstable mal","volume":"190","author":"Pirahmadi","year":"2019","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2026.128683_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274275","article-title":"Design and development of a self-assembling protein nanoparticle displaying PfHAP2 antigenic determinants recognized by natural acquired antibodies","volume":"17","author":"Zahedi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128683_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1099991","article-title":"A single vaccination of nucleoside-modified rabies mRNA vaccine induces prolonged highly protective immune responses in mice","volume":"13","author":"Bai","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0170","first-page":"433","article-title":"Modified ELISA for antibody avidity evaluation: The need for standardization","volume":"44","author":"Correa","year":"2021","journal-title":"Biom J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.molbiopara.2007.04.008","article-title":"Improved synchronous production of Plasmodium falciparum gametocytes in vitro","volume":"154","author":"Fivelman","year":"2007","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40794-024-00222-3","article-title":"A landscape review of malaria vaccine candidates in the pipeline","volume":"10","author":"Tajudeen","year":"2024","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/imcb.12415","article-title":"Epitope masking may limit antibody boosting to malaria vaccines","volume":"99","author":"Kurtovic","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0190","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.chom.2020.07.001","article-title":"Antibody feedback limits the expansion of B cell responses to malaria vaccination but drives diversification of the humoral response","volume":"28","author":"McNamara","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128683_bb0195","doi-asserted-by":"crossref","first-page":"12045","DOI":"10.1073\/pnas.1702944114","article-title":"Synergistic malaria vaccine combinations identified by systematic antigen screening","volume":"114","author":"Bustamante","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128683_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0117-2","article-title":"A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS, S malaria vaccine","volume":"12","author":"White","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128683_bb0205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/infdis\/jis709","article-title":"Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications","volume":"207","author":"Ouattara","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128683_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpara.2016.06.002","article-title":"Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria","volume":"47","author":"Boyle","year":"2017","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2026.128683_bb0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-023-00701-2","article-title":"Multifunctional IgG\/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine","volume":"8","author":"Rosenkranz","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN$\u03b3$ response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0225","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1086\/597121","article-title":"Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites","volume":"199","author":"Putrianti","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128683_bb0230","doi-asserted-by":"crossref","DOI":"10.59411\/990get50","article-title":"Status in malaria vaccine development: basic aspects of vaccine, mechanism of actions, vaccine pipelines, stage oriented immune response \u2018challenges and opportunities\u2019","volume":"3","author":"Taddese","year":"2023","journal-title":"Microb J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105203","article-title":"How can we develop an effective subunit vaccine to achieve successful malaria eradication?","volume":"160","author":"Pirahmadi","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2026.128683_bb0240","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128683_bb0245","series-title":"Immunopotentiators in modern vaccines","first-page":"265","article-title":"The development of the adjuvant system AS01: a combination of two immunostimulants MPL and QS-21 in liposomes","author":"Didierlaurent","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128683_bb0250","doi-asserted-by":"crossref","first-page":"107192","DOI":"10.1016\/j.isci.2023.107192","article-title":"Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission","volume":"26","author":"Rausch","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2026.128683_bb0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-021-00383-8","article-title":"Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine","volume":"6","author":"Singh","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128683_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-020-03368-5","article-title":"Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose","volume":"19","author":"Huang","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-021-04743-0","article-title":"Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria","volume":"14","author":"Yang","year":"2021","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2026.128683_bb0270","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","article-title":"A randomized controlled phase 1 trial of malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel\u00ae in healthy Malian adults","volume":"23","author":"Sagara","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128683_bb0275","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400188","article-title":"A vaccine to block Plasmodium falciparum transmission","volume":"4","author":"Healy","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.vaccine.2026.128683_bb0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12936-022-04173-y","article-title":"Evaluation of the Pfs25-IMX313\/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings","volume":"21","author":"Mulamba","year":"2022","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0285","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","author":"Shimp","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128683_bb0290","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.vaccine.2016.06.066","article-title":"Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay","volume":"34","author":"Miura","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128683_bb0295","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12936-016-1515-z","article-title":"An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2026.128683_bb0300","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/01621459.2017.1356313","article-title":"Statistical methods for standard membrane-feeding assays to measure transmission blocking or reducing activity in malaria","volume":"113","author":"Swihart","year":"2018","journal-title":"J Am Stat Assoc"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2026.128784","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:00:39Z","timestamp":1794474039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"alternative-id":["S0264410X26004913"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128683","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-antigen transmission-blocking malaria vaccine elicits Th1-biased antibody responses and SMFA-confirmed oocyst reduction in Anopheles stephensi","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128683"}}